https://www.selleckchem.com/pr....oducts/pyrotinib.htm
DPP-4 inhibitors suppressed the tendency for subsequent nocturnal hypoglycemia. This prospective observational exploratory study showed that DPP-4 inhibitors could suppress BG variability during hemodialysis sessions as well as subsequent nocturnal changes in patients with type 2 diabetes. ClinicalTrials.gov identifier, UMIN000012638. ClinicalTrials.gov identifier, UMIN000012638.With the availability of second-generation basal insulin analogs, insulin degludec (100 and 200 units/ml [degludec]) and insulin glargine 300 units/ml (glargi
Gefällt mir
Kommentar
Teilen
